Search results
Results from the WOW.Com Content Network
Alloxan, sometimes referred to as alloxan monohydrate, is an organic compound with the formula OC(NHCO) 2 C(OH) 2.It is classified as a derivative of pyrimidine.The anhydrous derivative OC(NHCO) 2 CO is also known, as well as a dimeric derivative.
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
Causing diabetes; some drugs cause blood glucose (sugar) to rise temporarily. Other cause it to rise permanently; if so they have caused diabetes. A chemical used as rat poison is an example. Diabetologist A doctor who sees and treats people with diabetes mellitus. Diabulimia
[3] A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction , non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.
For example, some people with diabetes require more insulin after drinking skim milk than they do after taking an equivalent amount of fat, protein, carbohydrate, and fluid in some other form. Their particular reaction to skimmed milk is different from other people with diabetes, but the same amount of whole milk is likely to cause a still ...
Diabetes is very common. The Centers for Disease Control and Prevention (CDC) notes that 38.4 million people in the United States are currently living with diabetes. That’s 11.6 percent of the ...
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. [7] It is used when dietary changes, exercise, and weight loss are not enough. [4]
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. [1] [2] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.